A Phase I Study Combining Ibrutinib With Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients With Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2018
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 31 Jan 2018 Results (n=21) assessing efficacy and safety of ibrutinib in combination with standard R-ICE for patients with rel/ref DLBCL, were published in the Blood.
- 24 Jan 2018 Status changed from active, no longer recruiting to completed.